Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617

Microvascular Research

Volumn 83, Issue 3, 2012, Pages 290-297

  Molnar, Nikolett ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANTIBODY; MEDI 3617; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CONTACT; CELL INTERACTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; MICROCIRCULATION; MYOCYTES, SMOOTH MUSCLE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

MUS MUSCULUS;

EID: 84859504938     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.02.008     Document Type: Article

References (43)

1. Anargyrou K., et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008, 93:451-454.
2. Armulik A., et al. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-523.
3. Augustin H.G., et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
4. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
5. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
6. Brown J.L., et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 2010, 9:145-156.
7. Carlson T.R., et al. Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 2001, 276:26516-26525.
8. Cines D.B., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
9. Davis S., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
10. Davis S., et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 2003, 10:38-44.
11. De Palma M., et al. Angiopoietin-2 regulates gene expression in Tie2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010, 70:5270-5280.
12. De Palma M., Naldini L. Angiopoietin-2 ties up macrophages in tumor angiogenesis. Clin. Cancer Res. 2011, 17:1-7.
13. Dejana E. Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol. 2004, 5:261-270.
14. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2:795-803.
15. Fiedler U., et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J. Biol. Chem. 2003, 278:1721-1727.
16. Fiedler U., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
17. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
18. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
19. Fukuhara S., et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol. 2008, 10:513-526.
20. Gavard J., et al. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev. Cell 2008, 14:25-36.
21. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
22. Helfrich I., et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 2009, 15:1384-1392.
23. Hu B., Cheng S.Y. Angiopoietin-2: development of inhibitors for cancer therapy. Curr. Oncol. Rep. 2009, 11:111-116.
24. Hu B., et al. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res. 2006, 66:775-783.
25. Huang Y.Q., et al. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002, 99:1646-1650.
26. Imanishi Y., et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 2007, 67:4254-4263.
27. Jain R.K., et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
28. Korff T., et al. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J. 2001, 15:447-457.
29. Krikun G., et al. Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem. Biophys. Res. Commun. 2000, 275:159-163.
30. Lauren J., et al. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?. Am. J. Pathol. 1998, 153:1333-1339.
31. Leow C.C., et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human xenograft models. Int. J. Oncol. 2012, doi:10.3892.
32. Lind A.J., et al. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005, 62:394-399.
33. Lowenstein C.J., et al. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc. Med. 2005, 15:302-308.
34. Maisonpierre P.C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
35. Mazzieri R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
36. Partanen J., et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol. 1992, 12:1698-1707.
37. Rondaij M.G., et al. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1002-1007.
38. Saharinen P., et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell Biol. 2008, 10:527-537.
39. Scharpfenecker M., et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J. Cell Sci. 2005, 118:771-780.
40. Schnurch H., Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993, 119:957-968.
41. Sie M., et al. The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J. Neurosurg. 2009, 110:147-155.
42. Tait C.R., Jones P.F. Angiopoietins in tumours: the angiogenic switch. J. Pathol. 2004, 204:1-10.
43. Tsutsui S., et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res. Treat. 2006, 98:261-266.